Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its price target boosted by equities researchers at Barclays from $32.00 to $33.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective indicates a potential upside of 65.50% from the company’s previous close.
Several other analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $41.00 price objective on shares of Syndax Pharmaceuticals in a research note on Monday, July 29th. Stifel Nicolaus raised their price target on Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 26th. Jefferies Financial Group started coverage on Syndax Pharmaceuticals in a research note on Friday, June 28th. They issued a “buy” rating and a $37.00 price objective on the stock. Scotiabank lowered Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 14th. Finally, Citigroup cut their price target on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $34.50.
Check Out Our Latest Stock Analysis on Syndax Pharmaceuticals
Syndax Pharmaceuticals Stock Up 1.8 %
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.11. The company had revenue of $3.50 million for the quarter. During the same period in the previous year, the business earned ($0.64) EPS. Syndax Pharmaceuticals’s revenue for the quarter was up 3499999990.0% compared to the same quarter last year. As a group, research analysts anticipate that Syndax Pharmaceuticals will post -3.64 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, CFO Keith A. Goldan bought 1,250 shares of the stock in a transaction on Friday, June 14th. The stock was purchased at an average price of $20.03 per share, with a total value of $25,037.50. Following the completion of the purchase, the chief financial officer now owns 52,623 shares of the company’s stock, valued at $1,054,038.69. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.10% of the company’s stock.
Institutional Investors Weigh In On Syndax Pharmaceuticals
Several large investors have recently modified their holdings of SNDX. nVerses Capital LLC acquired a new stake in shares of Syndax Pharmaceuticals during the second quarter worth $33,000. CWM LLC lifted its holdings in shares of Syndax Pharmaceuticals by 415.3% in the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock valued at $36,000 after purchasing an additional 1,358 shares in the last quarter. MeadowBrook Investment Advisors LLC acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter worth about $37,000. Quadrant Capital Group LLC raised its position in Syndax Pharmaceuticals by 158.3% in the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after buying an additional 1,496 shares during the last quarter. Finally, Signaturefd LLC lifted its stake in Syndax Pharmaceuticals by 2,874.6% in the 4th quarter. Signaturefd LLC now owns 3,748 shares of the company’s stock valued at $81,000 after acquiring an additional 3,622 shares in the last quarter.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
See Also
- Five stocks we like better than Syndax Pharmaceuticals
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 Stocks to Buy for a Soft Landing, If There Is One
- 3 Tickers Leading a Meme Stock Revival
- Why You Shouldn’t Count Out Tencent Music Stock After Earnings
- What Are Dividends? Buy the Best Dividend Stocks
- Why Meta Could Be A $600 Stock Within Weeks
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.